Xtant Medical Holdings, Inc.

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, ABT has a market cap of 183.4B. Regarding current trading prices, XTNT is priced at $0.59, while ABT trades at $107.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas ABT's P/E ratio is 28.37. In terms of profitability, XTNT's ROE is +0.04%, compared to ABT's ROE of +0.13%. Regarding short-term risk, XTNT is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check ABT's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, XTNT is priced at $0.59, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, XTNT's ROE is +0.04%, compared to BSX-PA's ROE of +0.13%. Regarding short-term risk, XTNT is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check BSX-PA's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, SYK has a market cap of 128.5B. Regarding current trading prices, XTNT is priced at $0.59, while SYK trades at $339.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas SYK's P/E ratio is 39.93. In terms of profitability, XTNT's ROE is +0.04%, compared to SYK's ROE of +0.15%. Regarding short-term risk, XTNT is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check SYK's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, MDT has a market cap of 110.7B. Regarding current trading prices, XTNT is priced at $0.59, while MDT trades at $86.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas MDT's P/E ratio is 24.08. In terms of profitability, XTNT's ROE is +0.04%, compared to MDT's ROE of +0.10%. Regarding short-term risk, XTNT is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check MDT's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, BSX has a market cap of 103.1B. Regarding current trading prices, XTNT is priced at $0.59, while BSX trades at $69.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas BSX's P/E ratio is 35.83. In terms of profitability, XTNT's ROE is +0.04%, compared to BSX's ROE of +0.13%. Regarding short-term risk, XTNT is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check BSX's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, EW has a market cap of 47.9B. Regarding current trading prices, XTNT is priced at $0.59, while EW trades at $82.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas EW's P/E ratio is 45.60. In terms of profitability, XTNT's ROE is +0.04%, compared to EW's ROE of +0.10%. Regarding short-term risk, XTNT is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check EW's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, BRKRP has a market cap of 40.8B. Regarding current trading prices, XTNT is priced at $0.59, while BRKRP trades at $273.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas BRKRP's P/E ratio is N/A. In terms of profitability, XTNT's ROE is +0.04%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, XTNT is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check BRKRP's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, DXCM has a market cap of 26.1B. Regarding current trading prices, XTNT is priced at $0.59, while DXCM trades at $67.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas DXCM's P/E ratio is 32.03. In terms of profitability, XTNT's ROE is +0.04%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, XTNT is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check DXCM's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, PHG has a market cap of 25.2B. Regarding current trading prices, XTNT is priced at $0.59, while PHG trades at $26.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas PHG's P/E ratio is 24.54. In terms of profitability, XTNT's ROE is +0.04%, compared to PHG's ROE of +0.08%. Regarding short-term risk, XTNT is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check PHG's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, STE has a market cap of 21.6B. Regarding current trading prices, XTNT is priced at $0.59, while STE trades at $217.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas STE's P/E ratio is 30.45. In terms of profitability, XTNT's ROE is +0.04%, compared to STE's ROE of +0.10%. Regarding short-term risk, XTNT is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check STE's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, ZBH has a market cap of 17.4B. Regarding current trading prices, XTNT is priced at $0.59, while ZBH trades at $89.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas ZBH's P/E ratio is 24.76. In terms of profitability, XTNT's ROE is +0.04%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, XTNT is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check ZBH's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, XTNT is priced at $0.59, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas ABMD's P/E ratio is 65.36. In terms of profitability, XTNT's ROE is +0.04%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, XTNT is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check ABMD's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, PODD has a market cap of 16B. Regarding current trading prices, XTNT is priced at $0.59, while PODD trades at $228.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas PODD's P/E ratio is 65.26. In terms of profitability, XTNT's ROE is +0.04%, compared to PODD's ROE of +0.17%. Regarding short-term risk, XTNT is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check PODD's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, SNN has a market cap of 13.6B. Regarding current trading prices, XTNT is priced at $0.59, while SNN trades at $32.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas SNN's P/E ratio is 22.33. In terms of profitability, XTNT's ROE is +0.04%, compared to SNN's ROE of +0.12%. Regarding short-term risk, XTNT is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check SNN's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, PEN has a market cap of 13.2B. Regarding current trading prices, XTNT is priced at $0.59, while PEN trades at $337.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas PEN's P/E ratio is 74.20. In terms of profitability, XTNT's ROE is +0.04%, compared to PEN's ROE of +0.13%. Regarding short-term risk, XTNT is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check PEN's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, XTNT is priced at $0.59, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas SWAV's P/E ratio is 78.76. In terms of profitability, XTNT's ROE is +0.04%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, XTNT is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check SWAV's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, XTNT is priced at $0.59, while ALGN trades at $176.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas ALGN's P/E ratio is 30.59. In terms of profitability, XTNT's ROE is +0.04%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, XTNT is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check ALGN's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, GMED has a market cap of 11.7B. Regarding current trading prices, XTNT is priced at $0.59, while GMED trades at $86.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas GMED's P/E ratio is 22.01. In terms of profitability, XTNT's ROE is +0.04%, compared to GMED's ROE of +0.12%. Regarding short-term risk, XTNT is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check GMED's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, BIO has a market cap of 7.1B. Regarding current trading prices, XTNT is priced at $0.59, while BIO trades at $265.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas BIO's P/E ratio is 9.49. In terms of profitability, XTNT's ROE is +0.04%, compared to BIO's ROE of +0.11%. Regarding short-term risk, XTNT is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check BIO's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, BIO-B has a market cap of 7.1B. Regarding current trading prices, XTNT is priced at $0.59, while BIO-B trades at $268.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas BIO-B's P/E ratio is 9.48. In terms of profitability, XTNT's ROE is +0.04%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, XTNT is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check BIO-B's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, GKOS has a market cap of 5.9B. Regarding current trading prices, XTNT is priced at $0.59, while GKOS trades at $102.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas GKOS's P/E ratio is -30.76. In terms of profitability, XTNT's ROE is +0.04%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, XTNT is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check GKOS's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, BRKR has a market cap of 5.1B. Regarding current trading prices, XTNT is priced at $0.59, while BRKR trades at $33.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas BRKR's P/E ratio is -222.20. In terms of profitability, XTNT's ROE is +0.04%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, XTNT is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check BRKR's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, XTNT is priced at $0.59, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas NARI's P/E ratio is -59.24. In terms of profitability, XTNT's ROE is +0.04%, compared to NARI's ROE of -0.00%. Regarding short-term risk, XTNT is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check NARI's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, TMDX has a market cap of 3.9B. Regarding current trading prices, XTNT is priced at $0.59, while TMDX trades at $113.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas TMDX's P/E ratio is 23.39. In terms of profitability, XTNT's ROE is +0.04%, compared to TMDX's ROE of +0.54%. Regarding short-term risk, XTNT is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check TMDX's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, XTNT is priced at $0.59, while IRTC trades at $117.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas IRTC's P/E ratio is -84.26. In terms of profitability, XTNT's ROE is +0.04%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, XTNT is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check IRTC's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, XTNT is priced at $0.59, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas AXNX's P/E ratio is -709.80. In terms of profitability, XTNT's ROE is +0.04%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, XTNT is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check AXNX's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, LIVN has a market cap of 3.4B. Regarding current trading prices, XTNT is priced at $0.59, while LIVN trades at $63.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas LIVN's P/E ratio is -13.98. In terms of profitability, XTNT's ROE is +0.04%, compared to LIVN's ROE of -0.21%. Regarding short-term risk, XTNT is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check LIVN's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, ITGR has a market cap of 2.9B. Regarding current trading prices, XTNT is priced at $0.59, while ITGR trades at $84.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas ITGR's P/E ratio is 29.12. In terms of profitability, XTNT's ROE is +0.04%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, XTNT is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check ITGR's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, XTNT is priced at $0.59, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas NUVA's P/E ratio is 75.00. In terms of profitability, XTNT's ROE is +0.04%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, XTNT is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check NUVA's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, ATEC has a market cap of 1.9B. Regarding current trading prices, XTNT is priced at $0.59, while ATEC trades at $12.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas ATEC's P/E ratio is -12.89. In terms of profitability, XTNT's ROE is +0.04%, compared to ATEC's ROE of -17.60%. Regarding short-term risk, XTNT is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check ATEC's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, ESTA has a market cap of 1.8B. Regarding current trading prices, XTNT is priced at $0.59, while ESTA trades at $65.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas ESTA's P/E ratio is -36.42. In terms of profitability, XTNT's ROE is +0.04%, compared to ESTA's ROE of -2.02%. Regarding short-term risk, XTNT is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check ESTA's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, PMI has a market cap of 1.8B. Regarding current trading prices, XTNT is priced at $0.59, while PMI trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas PMI's P/E ratio is -2.58. In terms of profitability, XTNT's ROE is +0.04%, compared to PMI's ROE of +1.64%. Regarding short-term risk, XTNT is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check PMI's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, TNDM has a market cap of 1.7B. Regarding current trading prices, XTNT is priced at $0.59, while TNDM trades at $24.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas TNDM's P/E ratio is -8.16. In terms of profitability, XTNT's ROE is +0.04%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, XTNT is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check TNDM's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, AORT has a market cap of 1.7B. Regarding current trading prices, XTNT is priced at $0.59, while AORT trades at $36.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas AORT's P/E ratio is 168.19. In terms of profitability, XTNT's ROE is +0.04%, compared to AORT's ROE of +0.02%. Regarding short-term risk, XTNT is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check AORT's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, AXGN has a market cap of 1.6B. Regarding current trading prices, XTNT is priced at $0.59, while AXGN trades at $31.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas AXGN's P/E ratio is -90.65. In terms of profitability, XTNT's ROE is +0.04%, compared to AXGN's ROE of -0.13%. Regarding short-term risk, XTNT is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check AXGN's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, INSP has a market cap of 1.6B. Regarding current trading prices, XTNT is priced at $0.59, while INSP trades at $54.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas INSP's P/E ratio is 10.99. In terms of profitability, XTNT's ROE is +0.04%, compared to INSP's ROE of +0.21%. Regarding short-term risk, XTNT is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check INSP's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, UFPT has a market cap of 1.5B. Regarding current trading prices, XTNT is priced at $0.59, while UFPT trades at $196.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas UFPT's P/E ratio is 21.81. In terms of profitability, XTNT's ROE is +0.04%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, XTNT is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check UFPT's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, XTNT is priced at $0.59, while PRCT trades at $25.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas PRCT's P/E ratio is -14.99. In terms of profitability, XTNT's ROE is +0.04%, compared to PRCT's ROE of -0.25%. Regarding short-term risk, XTNT is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check PRCT's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, XTNT is priced at $0.59, while AHCO trades at $10.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas AHCO's P/E ratio is -19.07. In terms of profitability, XTNT's ROE is +0.04%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, XTNT is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check AHCO's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, XTNT is priced at $0.59, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas HSKA's P/E ratio is -62.49. In terms of profitability, XTNT's ROE is +0.04%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, XTNT is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check HSKA's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, IRMD has a market cap of 1.3B. Regarding current trading prices, XTNT is priced at $0.59, while IRMD trades at $99.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas IRMD's P/E ratio is 56.86. In terms of profitability, XTNT's ROE is +0.04%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, XTNT is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check IRMD's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, XTNT is priced at $0.59, while LMRI trades at $12.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas LMRI's P/E ratio is -25.74. In terms of profitability, XTNT's ROE is +0.04%, compared to LMRI's ROE of -0.52%. Regarding short-term risk, XTNT is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check LMRI's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, XTNT is priced at $0.59, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas SILK's P/E ratio is -18.96. In terms of profitability, XTNT's ROE is +0.04%, compared to SILK's ROE of -0.35%. Regarding short-term risk, XTNT is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check SILK's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, XTNT is priced at $0.59, while CNMD trades at $36.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas CNMD's P/E ratio is 23.83. In terms of profitability, XTNT's ROE is +0.04%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, XTNT is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check CNMD's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, XTNT is priced at $0.59, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas FNA's P/E ratio is -19.83. In terms of profitability, XTNT's ROE is +0.04%, compared to FNA's ROE of -0.17%. Regarding short-term risk, XTNT is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check FNA's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, BFLY has a market cap of 1B. Regarding current trading prices, XTNT is priced at $0.59, while BFLY trades at $3.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas BFLY's P/E ratio is -12.81. In terms of profitability, XTNT's ROE is +0.04%, compared to BFLY's ROE of -0.35%. Regarding short-term risk, XTNT is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check BFLY's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, SSII has a market cap of 960.1M. Regarding current trading prices, XTNT is priced at $0.59, while SSII trades at $5.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas SSII's P/E ratio is -82.33. In terms of profitability, XTNT's ROE is +0.04%, compared to SSII's ROE of -0.30%. Regarding short-term risk, XTNT is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check SSII's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, INMD has a market cap of 857.2M. Regarding current trading prices, XTNT is priced at $0.59, while INMD trades at $13.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas INMD's P/E ratio is 9.46. In terms of profitability, XTNT's ROE is +0.04%, compared to INMD's ROE of +0.15%. Regarding short-term risk, XTNT is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check INMD's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, XTNT is priced at $0.59, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas CSII's P/E ratio is -20.83. In terms of profitability, XTNT's ROE is +0.04%, compared to CSII's ROE of -0.14%. Regarding short-term risk, XTNT is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check CSII's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, XTNT is priced at $0.59, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas CRY's P/E ratio is 425.71. In terms of profitability, XTNT's ROE is +0.04%, compared to CRY's ROE of +0.02%. Regarding short-term risk, XTNT is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check CRY's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, CBLL has a market cap of 697.5M. Regarding current trading prices, XTNT is priced at $0.59, while CBLL trades at $19.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas CBLL's P/E ratio is -12.69. In terms of profitability, XTNT's ROE is +0.04%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, XTNT is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check CBLL's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, IART has a market cap of 696.8M. Regarding current trading prices, XTNT is priced at $0.59, while IART trades at $8.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas IART's P/E ratio is -1.33. In terms of profitability, XTNT's ROE is +0.04%, compared to IART's ROE of -0.44%. Regarding short-term risk, XTNT is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check IART's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, XTNT is priced at $0.59, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas SRDX's P/E ratio is -34.66. In terms of profitability, XTNT's ROE is +0.04%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, XTNT is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check SRDX's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, AVNS has a market cap of 606.6M. Regarding current trading prices, XTNT is priced at $0.59, while AVNS trades at $13.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas AVNS's P/E ratio is -8.31. In terms of profitability, XTNT's ROE is +0.04%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, XTNT is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check AVNS's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, TCMD has a market cap of 585.7M. Regarding current trading prices, XTNT is priced at $0.59, while TCMD trades at $27.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas TCMD's P/E ratio is 31.83. In terms of profitability, XTNT's ROE is +0.04%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, XTNT is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check TCMD's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, BVS has a market cap of 582.7M. Regarding current trading prices, XTNT is priced at $0.59, while BVS trades at $9.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas BVS's P/E ratio is 26.21. In terms of profitability, XTNT's ROE is +0.04%, compared to BVS's ROE of +0.14%. Regarding short-term risk, XTNT is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check BVS's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, XTNT is priced at $0.59, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas APEN's P/E ratio is -9.43. In terms of profitability, XTNT's ROE is +0.04%, compared to APEN's ROE of -0.85%. Regarding short-term risk, XTNT is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check APEN's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, CTKB has a market cap of 577.2M. Regarding current trading prices, XTNT is priced at $0.59, while CTKB trades at $4.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas CTKB's P/E ratio is -8.63. In terms of profitability, XTNT's ROE is +0.04%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, XTNT is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check CTKB's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, SIBN has a market cap of 564.9M. Regarding current trading prices, XTNT is priced at $0.59, while SIBN trades at $12.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas SIBN's P/E ratio is -29.07. In terms of profitability, XTNT's ROE is +0.04%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, XTNT is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check SIBN's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, BWAY has a market cap of 535.8M. Regarding current trading prices, XTNT is priced at $0.59, while BWAY trades at $13.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas BWAY's P/E ratio is 75.89. In terms of profitability, XTNT's ROE is +0.04%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, XTNT is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check BWAY's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, XTNT is priced at $0.59, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, XTNT's ROE is +0.04%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, XTNT is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check ZIMV's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, OFIX has a market cap of 467.7M. Regarding current trading prices, XTNT is priced at $0.59, while OFIX trades at $11.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas OFIX's P/E ratio is -5.00. In terms of profitability, XTNT's ROE is +0.04%, compared to OFIX's ROE of -0.20%. Regarding short-term risk, XTNT is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check OFIX's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, VREX has a market cap of 446.9M. Regarding current trading prices, XTNT is priced at $0.59, while VREX trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas VREX's P/E ratio is -6.50. In terms of profitability, XTNT's ROE is +0.04%, compared to VREX's ROE of -0.14%. Regarding short-term risk, XTNT is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check VREX's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, NPCE has a market cap of 437.7M. Regarding current trading prices, XTNT is priced at $0.59, while NPCE trades at $13.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas NPCE's P/E ratio is -19.70. In terms of profitability, XTNT's ROE is +0.04%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, XTNT is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check NPCE's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, KIDS has a market cap of 417.6M. Regarding current trading prices, XTNT is priced at $0.59, while KIDS trades at $16.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas KIDS's P/E ratio is -9.78. In terms of profitability, XTNT's ROE is +0.04%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, XTNT is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check KIDS's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, PACB has a market cap of 401.7M. Regarding current trading prices, XTNT is priced at $0.59, while PACB trades at $1.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas PACB's P/E ratio is -0.73. In terms of profitability, XTNT's ROE is +0.04%, compared to PACB's ROE of -11.23%. Regarding short-term risk, XTNT is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check PACB's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, LAB has a market cap of 378.6M. Regarding current trading prices, XTNT is priced at $0.59, while LAB trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas LAB's P/E ratio is -6.56. In terms of profitability, XTNT's ROE is +0.04%, compared to LAB's ROE of -0.18%. Regarding short-term risk, XTNT is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check LAB's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, VMD has a market cap of 336.2M. Regarding current trading prices, XTNT is priced at $0.59, while VMD trades at $9.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas VMD's P/E ratio is 23.54. In terms of profitability, XTNT's ROE is +0.04%, compared to VMD's ROE of +0.11%. Regarding short-term risk, XTNT is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check VMD's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, CERS has a market cap of 329.6M. Regarding current trading prices, XTNT is priced at $0.59, while CERS trades at $1.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas CERS's P/E ratio is -21.44. In terms of profitability, XTNT's ROE is +0.04%, compared to CERS's ROE of -0.26%. Regarding short-term risk, XTNT is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check CERS's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, CATX has a market cap of 327.4M. Regarding current trading prices, XTNT is priced at $0.59, while CATX trades at $4.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas CATX's P/E ratio is -2.94. In terms of profitability, XTNT's ROE is +0.04%, compared to CATX's ROE of -0.41%. Regarding short-term risk, XTNT is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check CATX's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, DCTH has a market cap of 315.1M. Regarding current trading prices, XTNT is priced at $0.59, while DCTH trades at $9.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas DCTH's P/E ratio is 129.57. In terms of profitability, XTNT's ROE is +0.04%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, XTNT is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check DCTH's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, XTNT is priced at $0.59, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas SMLR's P/E ratio is 3.92. In terms of profitability, XTNT's ROE is +0.04%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, XTNT is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check SMLR's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, SENS has a market cap of 270.7M. Regarding current trading prices, XTNT is priced at $0.59, while SENS trades at $6.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas SENS's P/E ratio is -3.90. In terms of profitability, XTNT's ROE is +0.04%, compared to SENS's ROE of -1.04%. Regarding short-term risk, XTNT is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check SENS's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, CLPT has a market cap of 268.3M. Regarding current trading prices, XTNT is priced at $0.59, while CLPT trades at $9.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas CLPT's P/E ratio is -10.87. In terms of profitability, XTNT's ROE is +0.04%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, XTNT is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check CLPT's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, RXST has a market cap of 265.8M. Regarding current trading prices, XTNT is priced at $0.59, while RXST trades at $6.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas RXST's P/E ratio is -6.78. In terms of profitability, XTNT's ROE is +0.04%, compared to RXST's ROE of -0.14%. Regarding short-term risk, XTNT is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check RXST's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, XTNT is priced at $0.59, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas MGRM's P/E ratio is -11.11. In terms of profitability, XTNT's ROE is +0.04%, compared to MGRM's ROE of -1.37%. Regarding short-term risk, XTNT is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check MGRM's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, MASS has a market cap of 228.4M. Regarding current trading prices, XTNT is priced at $0.59, while MASS trades at $6.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas MASS's P/E ratio is -6.57. In terms of profitability, XTNT's ROE is +0.04%, compared to MASS's ROE of +0.13%. Regarding short-term risk, XTNT is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check MASS's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, CVRX has a market cap of 228.1M. Regarding current trading prices, XTNT is priced at $0.59, while CVRX trades at $8.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas CVRX's P/E ratio is -4.25. In terms of profitability, XTNT's ROE is +0.04%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, XTNT is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check CVRX's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, XTNT is priced at $0.59, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas NVRO's P/E ratio is -1.91. In terms of profitability, XTNT's ROE is +0.04%, compared to NVRO's ROE of -0.27%. Regarding short-term risk, XTNT is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check NVRO's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, XTNT is priced at $0.59, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas EYES's P/E ratio is N/A. In terms of profitability, XTNT's ROE is +0.04%, compared to EYES's ROE of -4.16%. Regarding short-term risk, XTNT is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check EYES's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, AVR has a market cap of 206.4M. Regarding current trading prices, XTNT is priced at $0.59, while AVR trades at $5.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas AVR's P/E ratio is -2.20. In terms of profitability, XTNT's ROE is +0.04%, compared to AVR's ROE of -5.28%. Regarding short-term risk, XTNT is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check AVR's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, QTRX has a market cap of 200.9M. Regarding current trading prices, XTNT is priced at $0.59, while QTRX trades at $4.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas QTRX's P/E ratio is -1.71. In terms of profitability, XTNT's ROE is +0.04%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, XTNT is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check QTRX's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, ANIK has a market cap of 199.8M. Regarding current trading prices, XTNT is priced at $0.59, while ANIK trades at $14.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas ANIK's P/E ratio is -19.79. In terms of profitability, XTNT's ROE is +0.04%, compared to ANIK's ROE of -0.07%. Regarding short-term risk, XTNT is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check ANIK's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, ELMD has a market cap of 192.7M. Regarding current trading prices, XTNT is priced at $0.59, while ELMD trades at $23.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas ELMD's P/E ratio is 22.44. In terms of profitability, XTNT's ROE is +0.04%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, XTNT is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check ELMD's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, XTNT is priced at $0.59, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas BSGM's P/E ratio is -5.81. In terms of profitability, XTNT's ROE is +0.04%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, XTNT is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check BSGM's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, QTI has a market cap of 188.6M. Regarding current trading prices, XTNT is priced at $0.59, while QTI trades at $7.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas QTI's P/E ratio is -3.46. In terms of profitability, XTNT's ROE is +0.04%, compared to QTI's ROE of +3.64%. Regarding short-term risk, XTNT is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check QTI's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, SGHT has a market cap of 187.4M. Regarding current trading prices, XTNT is priced at $0.59, while SGHT trades at $3.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas SGHT's P/E ratio is -4.69. In terms of profitability, XTNT's ROE is +0.04%, compared to SGHT's ROE of -0.56%. Regarding short-term risk, XTNT is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check SGHT's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, XTNT is priced at $0.59, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas MDGS's P/E ratio is -0.27. In terms of profitability, XTNT's ROE is +0.04%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, XTNT is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check MDGS's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, SNWV has a market cap of 173.2M. Regarding current trading prices, XTNT is priced at $0.59, while SNWV trades at $20.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas SNWV's P/E ratio is -27.67. In terms of profitability, XTNT's ROE is +0.04%, compared to SNWV's ROE of +0.59%. Regarding short-term risk, XTNT is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check SNWV's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, INGN has a market cap of 166.1M. Regarding current trading prices, XTNT is priced at $0.59, while INGN trades at $6.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas INGN's P/E ratio is -7.09. In terms of profitability, XTNT's ROE is +0.04%, compared to INGN's ROE of -0.12%. Regarding short-term risk, XTNT is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check INGN's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, XTNT is priced at $0.59, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas QIPT's P/E ratio is -15.87. In terms of profitability, XTNT's ROE is +0.04%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, XTNT is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check QIPT's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, NNOX has a market cap of 153.7M. Regarding current trading prices, XTNT is priced at $0.59, while NNOX trades at $2.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas NNOX's P/E ratio is -2.74. In terms of profitability, XTNT's ROE is +0.04%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, XTNT is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check NNOX's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, PROF has a market cap of 153.1M. Regarding current trading prices, XTNT is priced at $0.59, while PROF trades at $5.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas PROF's P/E ratio is -3.59. In terms of profitability, XTNT's ROE is +0.04%, compared to PROF's ROE of -0.80%. Regarding short-term risk, XTNT is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check PROF's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, TLSI has a market cap of 149M. Regarding current trading prices, XTNT is priced at $0.59, while TLSI trades at $3.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas TLSI's P/E ratio is -2.14. In terms of profitability, XTNT's ROE is +0.04%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, XTNT is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check TLSI's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, APYX has a market cap of 144.3M. Regarding current trading prices, XTNT is priced at $0.59, while APYX trades at $3.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas APYX's P/E ratio is -12.78. In terms of profitability, XTNT's ROE is +0.04%, compared to APYX's ROE of -1.18%. Regarding short-term risk, XTNT is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check APYX's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, EDAP has a market cap of 135.7M. Regarding current trading prices, XTNT is priced at $0.59, while EDAP trades at $3.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas EDAP's P/E ratio is -6.60. In terms of profitability, XTNT's ROE is +0.04%, compared to EDAP's ROE of -0.62%. Regarding short-term risk, XTNT is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check EDAP's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, LUCD has a market cap of 127.2M. Regarding current trading prices, XTNT is priced at $0.59, while LUCD trades at $1.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas LUCD's P/E ratio is -1.62. In terms of profitability, XTNT's ROE is +0.04%, compared to LUCD's ROE of -6.32%. Regarding short-term risk, XTNT is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for XTNT.Check LUCD's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, FONR has a market cap of 113.4M. Regarding current trading prices, XTNT is priced at $0.59, while FONR trades at $18.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas FONR's P/E ratio is 15.98. In terms of profitability, XTNT's ROE is +0.04%, compared to FONR's ROE of +0.04%. Regarding short-term risk, XTNT is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check FONR's competition here

XTNT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XTNT stands at 85.4M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, XTNT is priced at $0.59, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XTNT currently has a P/E ratio of 60.99, whereas ICAD's P/E ratio is -20.37. In terms of profitability, XTNT's ROE is +0.04%, compared to ICAD's ROE of -0.12%. Regarding short-term risk, XTNT is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for XTNT.Check ICAD's competition here